Human iPSC-Derived Mesodermal Precursor Cells and Differentiated Cells

Cells, cell culture methods, and cell culture media compositions useful for producing and maintaining iPSC-derived cell lines that are of higher purity and maintain cell type integrity better than current iPSC-derived cell lines are disclosed. Human induced pluripotent stem cells (hiPSCs) can be generated by reprogramming somatic cells by the expression of four transcription factors. The hiPSCs exhibit similar properties to human embryonic stem cells, including the ability to self-renew and differentiate into all three embryonic germ layers: ectoderm, endoderm, or mesoderm. Human iPSCs can be induced into any cell type and, since they can be maintained over many passages, they can serve as an almost unlimited source to generate cells from any given person. These properties make iPSC-derived cells a valuable product for cell therapies and toxicology or pharmaceutical high throughput screens. NIH investigators disclose an iPSC-derived mesodermal precursor cell line, positive for CD34 and CD31 expression, that may be used to produce at least four different cell types. When cultured under appropriate conditions, these mesodermal precursor cells can be used to produce hematopoietic stem cells, mesenchymal stem cells, smooth muscle cells, or unlimited functional endothelial cells.

Potential Commercial Applications: Competitive Advantages:
  • The iPSC-derived mesodermal precursor cell (MPC) line described here can be used to produce hematopoietic stem cells, mesenchymal stem cells , smooth muscle cells, or unlimited functional endothelial cells.
  • The differentiated cells produced using the disclosed methods and MPC can be used for screening, as well as therapeutic applications.
  • The mesodermal precursor cells have the ability to maintain their phenotype for extended periods without differentiating, when maintained under appropriate conditions.

Related Inventoion(s):

Manfred Boehm (NHLBI)
Guibin Chen (NHLBI)
Mahendra Rao (NIA)
Andre Larochelle (NHLBI)

Intellectual Property:
US Application No. 61/885,209

Collaboration Opportunity:

The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Denise Crooks at

Licensing Contact:
Suryanarayana Vepa , Ph.D.
NIH Office of Technology Transfer
Phone: 301-435-5020

OTT Reference No: E-342-2013/0

Updated: Mar-18-2014